Global Heart Block Therapeutics Market was valued at US$ 3 Bn in 2021 and is expected toreach US$ 4.8 Bn by 2032, find Future Market Insights (FMI) in arecent market survey. As per thefindings of the report, Pacemakers, among all products will garner significant
demand in the market as the bulk of revenue will be generated through them.
Revenue through pacemakers grew at a CAGR of 4.8% during 2015 -2021.
Older Populace Swells Worldwide,Propels the Global Demand for Heart Block Therapeutics
According to the United NationsDepartment of Economic and Social Affairs, by 2050, the population of 60 years
old and above is expected to reach 437 Mn in China, 324 Mn in India, 107 Mn in
The US, and 58 Mn in Brazil. Hence, the growing older populace propels the
worldwide Heart Block Therapeutics market as the older population is more prone
to heart-related diseases. The World Health Organization (WHO) reported that
around 524 Mn people represent the geriatric population in 2010 and by 2050,
almost 2 Bn people will be geriatric.
The US Continues Being the LargestRevenue Stream for Heart Block Therapeutics Market
Heart Block Therapeutics market in theUS to reach a valuation of US$ 1.7 Bn by 2032. From 2015 to2021, the market revenue through the US grew at a CAGR of 4.7%,while between 2022 and 2032, it is predicted to witness a CAGR of 4.1%.The combination of innovative treatment technology, adoption of digital
solutions, and shifting provider and care delivery shifts provides the Heart
Block Therapeutics Industry with tremendous growth potential in the United
States. Between 2022 and 2032, the US is expected to be a market with a US$570.5 Mn absolute dollar opportunity.
“Introduction of artificialintelligence technology in the Heart Blockage surgeries will be the biggest
step towards increasing the revenue growth of Heart Block Therapeutics Market” comments an analyst at Future MarketInsights.
Heart Block Therapeutics Market: Competition Insights
The key companies dominating the HeartBlock Therapeutics Market are St. Jude Medical, Medtronic, Bristol Myers
Squibb, Novartis AG, Boston Scientific Corporation, BIOTRONIK SE & Co. KG,
Edward Lifesciences Corporation, Abbott Laboratories, Natco Pharma, Pfizer
Inc., Bayer AG, Astra Zeneca, Sanofi, Merck & Co., Inc., Gilead Sciences,
Inc., F. Hoffmann-La Roche Ltd.
Some of the recent developments by the keyproviders of Heart Block Therapeutics are as follows:
- In April 2022, Bristol Myers Squibb announced that they have received approval from US Food and Drug
Corporation for its oral heart disease drug Mavacamten which will help in
treating hypertrophic cardiomyopathy, a genetic heart disease that leads
to sudden cardiac arrests in young people. - In June 2020, Edward Lifesciences Corporation (USA) confirmed that they have received Chinese
approval for the SAPIEN 3 Trans catheter heart valve for the treatment of
patients with severe and symptomatic aortic stenosis (AS) who are not able
to undergo open-heart surgery. - In September 2019, Medtronic (USA) Received US Food and Drug Corporation clearance for its
Next Generation Evolut PRO+ TAVR System for the Treatment of Symptomatic
Severe Aortic Stenosis in Patients. The Evolut PRO+ TAVR System includes
four valve sizes with an external pericardial tissue wrap that provides
advanced sealing for the largest indicated patient treatment range and the
lowest delivery profile currently on the market. - In March 2019, Abbott (USA) Received US Food and Drug Corporation Clearance Anthos Therapeutics for
Cardiovascular Drug Development which focused on advancing next-generation
targeted therapies for high-risk cardiovascular
patients. - In February 2019, Novartis AG and Blackstone’s Life sciences announced the launch of Anthos Therapeutics for
the development of cardiovascular drugs. As part of this launch, Novartis
has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa,
key components of the intrinsic coagulation pathway. - In January 2019, India-based Natco Pharma announced the launch of valsartan sacubitril, a
cardiovascular drug that is used to treat congestive heart failure in
patients.
Key Segments Coveredin Heart Block Therapeutics Market Survey
- By Type:
- First Degree Heart Blocks
- Second Degree Heart Blocks
- Third Degree Heart Blocks
- By Product:
- Transcutaneous pacing (TCP)
- Pacemaker
- Mediation
- Follow-up electrophysiology study
- By End User:
- Hospital Testing
- Home Treatment
- Clinics
- Others
- By Region:
- North America
- Europe
- APAC
- MEA
- Latin America
Information Source:
